326 related articles for article (PubMed ID: 31520872)
1. Clinical evaluation of [
Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M
Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [
Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
[TBL] [Abstract][Full Text] [Related]
4. Altered biodistribution of [
van de Weijer T; Bemer F; de Vos-Geelen J; Hermans B; Mitea C; van der Pol JAJ; Lodewick T; Wildberger JE; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723
[TBL] [Abstract][Full Text] [Related]
5. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
8. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
11. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
12. Changes in biodistribution on
Cherk MH; Kong G; Hicks RJ; Hofman MS
Cancer Imaging; 2018 Jan; 18(1):3. PubMed ID: 29361984
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
14. Instant kit preparation of
Sinnes JP; Nagel J; Waldron BP; Maina T; Nock BA; Bergmann RK; Ullrich M; Pietzsch J; Bachmann M; Baum RP; Rösch F
EJNMMI Res; 2019 May; 9(1):48. PubMed ID: 31123943
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma.
Schartinger VH; Dudás J; Url C; Reinold S; Virgolini IJ; Kroiss A; Riechelmann H; Uprimny C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):20-4. PubMed ID: 25227762
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
18.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
19. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [
Nogareda Seoane Z; Mallón Araújo MC; Calatayud Cubes A; Barberán Corral C; Domínguez Novoa Y; Cousillas Castiñeira A; Martínez Lago N; de Matías Leralta JM; Pubul Nuñez V
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500011. PubMed ID: 38643835
[TBL] [Abstract][Full Text] [Related]
20. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
